AUS
NZ
UK
CA
USA
IND
Highlights
ResMed delivers robust FY25 results
Strong demand in sleep and digital health solutions
Operational efficiencies support margin growth
ResMed, a prominent player in respiratory and sleep health, has reported a strong finish to fiscal year 2025. The healthcare technology company, which is part of the ASX 200, showed notable performance across its core product lines and software offerings. This momentum was supported by increasing global demand for sleep devices and strategic advancements in digital health.
With a presence in sleep apnea treatment, COPD management, and digital care platforms, ResMed’s recent update underscores its growth trajectory and operational discipline.
FY25 Fourth Quarter Performance Strengthens
In the final quarter of FY25, ResMed (ASX:RMD) witnessed a rise in both revenue. Demand for its masks and sleep devices remained strong across multiple regions, contributing significantly to its topline performance. The company’s residential care software platform also continued to gain traction, offering remote care capabilities that align with modern healthcare delivery trends.
ResMed attributed part of its success to operational efficiencies particularly in areas like procurement, logistics, and manufacturing which supported margin growth and overall financial health.
Full-Year Growth Driven by Diversified Portfolio
For the full year, ResMed delivered solid growth across key business segments. Its core medical devices segment remained the backbone of operations, while the expansion of its digital health ecosystem played a pivotal role in scaling patient access and engagement.
The integrated delivery of care through both devices and cloud-based software helped ResMed reach a wider population, enabling at-home respiratory monitoring and therapy. This dual approach hardware plus software continues to differentiate the business in a rapidly evolving healthcare landscape.
Such a strategy is not only meeting current healthcare needs but also positions ResMed to support long-term global health challenges related to respiratory disorders and sleep conditions.
Vision for FY26 and Beyond
As the company transitions into the new fiscal year, its focus remains on advancing innovation and expanding global access to sleep and breathing care. Plans include enhancing digital solutions, expanding partnerships with healthcare providers, and strengthening relationships with healthcare policymakers and payers.
The goal is clear: to ensure more people across the globe can access effective sleep and respiratory therapies from the comfort of their homes. ResMed’s consistent performance and forward-looking approach reflect its commitment to improving health outcomes through connected care.
With a solid foundation and strategic vision, ResMed is positioned for continued momentum in FY26.
Frequently Asked Questions
- What does ResMed (ASX:RMD) specialise in?
ResMed develops solutions for sleep apnea, COPD, and other chronic respiratory conditions through devices and digital platforms. - What contributed to ResMed’s strong FY25 performance?
A combination of strong global demand for sleep-related devices, software-driven care solutions, and operational efficiencies contributed to the company’s robust results. - Is ResMed included in the ASX 200 index?
Yes, ResMed is part of the ASX 200, which comprises the 200 largest listed companies on the Australian Securities Exchange.
